Immunotherapy for patients with pancreatic adenocarcinoma

Article Properties
Cite
John, Stanislav. “Immunotherapy for Patients With Pancreatic Adenocarcinoma”. Onkologie, vol. 16, no. 3, 2022, pp. 127-9, https://doi.org/10.36290/xon.2022.025.
John, S. (2022). Immunotherapy for patients with pancreatic adenocarcinoma. Onkologie, 16(3), 127-129. https://doi.org/10.36290/xon.2022.025
John S. Immunotherapy for patients with pancreatic adenocarcinoma. Onkologie. 2022;16(3):127-9.
Refrences
Title Journal Journal Categories Citations Publication Date
10.1200/JCO.2006.07.9525
10.1056/NEJMoa1903387
The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives

 Signal Transduction and Targeted Therapy
  • Medicine
  • Science: Biology (General)
  • Science: Biology (General)
  • Science: Biology (General): Cytology
  • Science: Biology (General): Genetics
 115 2021
FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study World Journal of Gastrointestinal Oncology
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Internal medicine: Specialties of internal medicine: Diseases of the digestive system. Gastroenterology
  • Medicine: Medicine (General)
 6 2020
Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT) BMC Cancer
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Medicine (General)
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
 22 2016